The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Status:
Completed
Trial end date:
1996-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus
placebo in reducing the transfusion requirements in anemic patients with multiple myeloma,
and to investigate the quality-of-life benefits associated with the use of epoetin alfa.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.